DekaBank Deutsche Girozentrale boosted its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 6.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 855,037 shares of the biopharmaceutical company’s stock after buying an additional 53,474 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Bristol-Myers Squibb were worth $47,492,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. American National Bank boosted its stake in Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC boosted its stake in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares in the last quarter. Crestwood Advisors Group LLC purchased a new stake in Bristol-Myers Squibb during the first quarter valued at about $116,000. State of Alaska Department of Revenue boosted its stake in Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 60 shares during the period. Finally, Prentiss Smith & Co. Inc. boosted its stake in Bristol-Myers Squibb by 61.8% in the first quarter. Prentiss Smith & Co. Inc. now owns 2,333 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 891 shares during the period. Institutional investors and hedge funds own 69.63% of the company’s stock.

Shares of Bristol-Myers Squibb Company (BMY) opened at 54.79 on Tuesday. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $77.12. The firm has a 50-day moving average of $54.58 and a 200-day moving average of $55.03. The company has a market cap of $90.26 billion, a price-to-earnings ratio of 19.03 and a beta of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.12. Bristol-Myers Squibb had a net margin of 24.22% and a return on equity of 31.86%. The business had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.75 billion. During the same quarter in the prior year, the firm posted $0.74 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts forecast that Bristol-Myers Squibb Company will post $2.95 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, August 1st. Investors of record on Friday, July 7th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.85%. The ex-dividend date of this dividend is Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 54.17%.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (NYSE:BMY) Shares Bought by DekaBank Deutsche Girozentrale” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/07/18/bristol-myers-squibb-company-nysebmy-shares-bought-by-dekabank-deutsche-girozentrale.html.

Several analysts have recently weighed in on BMY shares. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $61.64 price objective on the stock in a research report on Tuesday, March 21st. BMO Capital Markets cut shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research report on Wednesday, May 3rd. Robert W. Baird started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 25th. They set an “outperform” rating on the stock. Jefferies Group LLC restated a “buy” rating and set a $64.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, June 5th. Finally, BidaskClub cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $63.26.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.